echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Taizhou Institute of Health Sciences of Fudan University and Kunyuan Biotechnology launch large-scale early screening of pan-cancer species

    Taizhou Institute of Health Sciences of Fudan University and Kunyuan Biotechnology launch large-scale early screening of pan-cancer species

    • Last Update: 2021-12-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On November 21, the Taizhou Institute of Health Sciences of Fudan University, together with Shanghai Kunyuan Biotechnology Co.
    , Ltd.
    and Shanghai International Human Phenotypic Research Institute, and 11 domestic tertiary hospitals launched the "Fusheng Project" Chinese population pan-cancer early screening in Shanghai Research
    .


    This is the largest and most extensive prospective study of pan-cancer early screening in China so far.


    In July 2020, the team from the Taizhou Institute of Health Sciences of Fudan University used the circulating tumor DNA (ctDNA) methylation pan-cancer screening technology PanSeer® independently developed by Kunyuan Biotechnology to achieve the first pan-cancer early screening technology in a large natural population cohort The related research results are published in the international authoritative academic journal "Nature Communications"
    .


    The study found that the application of ctDNA methylation markers has achieved "early warning" of lung cancer, four years in advanceGastric cancer , esophageal cancer, liver cancer and rectal cancer are five common malignant tumors, with a sensitivity of 95% and a specificity of 96%


    ScreeningStomach cancer

    The "Fusheng Project" Chinese population pan-cancer early screening project launched this time will further promote in-depth research in the field of pan-cancer early screening, aiming to establish a pan-cancer early screening model suitable for the Chinese population, and Accelerate the transformation of cutting-edge innovation achievements and the development of related application products in response to the strategic needs of people's health
    .

    The "Fusheng Project" expert committee consists of more than 30 top-notch experts including Academician Wang Chen of the Chinese Academy of Medical Sciences, Academician Shen Hongbing of Nanjing Medical University, Academician Zhou Honghao of Central South University, Academician Zhao Guoping of the Shanghai Branch of Chinese Academy of Sciences, and Academician Jinli of Taizhou Institute of Health Sciences of Fudan University Composition of experts
    .

    According to the 2020 global cancer burden data released by the International Agency for Research on Cancer (IARC) of the World Health Organization, there will be 4.
    57 million new cancer cases and 3 million cancer deaths in China in 2020
    .


    The number of new cancers and cancer deaths rank first in the world.


    Cancer screening and early diagnosis and treatment have been recognized as the most effective means of cancer prevention and control
    .


    In recent years, with the breakthrough of liquid biopsy technology, various early cancer screening products continue to emerge


    Jin Li, an academician of the Chinese Academy of Sciences, said: Cancer prevention and control is the main battlefield of disease prevention and control in China.
    On the one hand, it is necessary to increase the research and development of clinical diagnosis and treatment technologies and drugs to serve the majority of patients; In the field of early diagnosis and early intervention, we will give full play to the power of science and technology to develop biomarkers that can be used for early screening of cancers, increase the rate of early diagnosis of cancer, and reduce the burden of disease
    .


    The state has issued a series of policies to effectively promote early cancer screening, and through the "13th Five-Year Plan" and "14th Five-Year Plan" key special projects, promote the technological innovation of early cancer screening


    Jin Li, academician of the Chinese Academy of Sciences, said: Diagnosis, treatment and diagnosis

    Shen Hongbing, an academician of the Chinese Academy of Engineering, said: Playing the leading and supporting role of scientific and technological innovation and establishing new technologies and new programs for cancer screening and early diagnosis in line with China's national conditions are essential for the implementation of early diagnosis and treatment
    .


    China is currently facing a complex situation of cancer prevention and control coexisting in both developing and developed countries.


    Shen Hongbing, Academician of Chinese Academy of Engineering

    Zhou Honghao, an academician of the Chinese Academy of Engineering, said: Precision medicine has been developed in China for more than 30 years.
    Genetic testing plays a huge role in promoting disease prediction, prevention, and individualized treatment, and leading the industrialization of major innovations.
    Early cancer screening is an example.
    The application of genetic testing is flourishing
    .


    This pan-cancer early screening project makes full use of the advantages of Fudan University's multidisciplinary and interdisciplinary scientific research, and combines the advantages of experts from many top domestic hospitals.


    Zhou Honghao, academician of the Chinese Academy of Engineering, precision prevention

    Zhao Guoping, an academician of the Chinese Academy of Sciences, said: There are no obvious symptoms and signs in the early stage of cancer; there is a lack of specific, clear, and simple preliminary screening indicators for cancer risk factors; traditional cancer screening methods have a series of limitations
    .


    With the development of modern molecular biology and genomics technology, people can carry out early screening, clinical diagnosis and prognostic evaluation of malignant tumors at the molecular level, providing key information for tumor prevention and control and individualized treatment


    Zhao Guoping, Academician of the Chinese Academy of Sciences

    Zhang Jiangli, co-founder and CEO of Kunyuan Biotech, said : "Fusheng Project" covers a wide range of regions.
    The large-sample, multi-omics prospective study launched this time can better optimize and validate the PanSeer® multi-cancer screen.
    Check the model, and accelerate the commercialization under the premise of mature verification
    .
    Fudan University's profound basic research background, as well as the advantages of multi-disciplinary research, coupled with the rich sample resources of the Taizhou cohort, have laid a solid foundation for the development of the project.
    Kunyuan Biology will further deepen its cooperation with Fudan University Taizhou Health Science Comprehensive cooperation of the institute
    .
    Since its establishment, Kunyuan has always insisted on the research and development of the underlying original technology.
    The company will continue to use its technological advantages to contribute its own strength to the healthy China cancer prevention and control initiative
    .

    Zhang Jiangli, co-founder and CEO of Kunyuan Biotech, expressed his message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.